These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1653684)

  • 1. Inhibitory effects of quinolones on murine hematopoietic progenitor cells and eukaryotic topoisomerase II.
    Akahane K; Hoshino K; Sato K; Kimura Y; Une T; Osada Y
    Chemotherapy; 1991; 37(3):224-6. PubMed ID: 1653684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.
    Hoshino K; Sato K; Une T; Osada Y
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1816-8. PubMed ID: 2556080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fluoroquinolones on the in-vitro proliferation of myeloid precursor cells.
    Pessina A; Neri MG; Muschiato A; Mineo E; Cocuzza G
    J Antimicrob Chemother; 1989 Aug; 24(2):203-8. PubMed ID: 2793643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential.
    Elsea SH; McGuirk PR; Gootz TD; Moynihan M; Osheroff N
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2179-86. PubMed ID: 8257142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fleroxacin on HeLa cell functions and topoisomerase II.
    Oomori Y; Yasue T; Aoyama H; Hirai K; Suzue S; Yokota T
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():91-7. PubMed ID: 2849603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.
    Barrett JF; Gootz TD; McGuirk PR; Farrell CA; Sokolowski SA
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1697-703. PubMed ID: 2556075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme.
    Froelich-Ammon SJ; McGuirk PR; Gootz TD; Jefson MR; Osheroff N
    Antimicrob Agents Chemother; 1993 Apr; 37(4):646-51. PubMed ID: 8388196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
    Takei M; Fukuda H; Kishii R; Hosaka M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282.
    Kohlbrenner WE; Wideburg N; Weigl D; Saldivar A; Chu DT
    Antimicrob Agents Chemother; 1992 Jan; 36(1):81-6. PubMed ID: 1317151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961.
    Fabbri S; Broggini M; Pagella P; D'Incalci M
    J Antimicrob Chemother; 1991 May; 27(5):687-9. PubMed ID: 1653205
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative in vitro studies with 4-quinolone antimicrobials.
    Felmingham D; O'Hare MD; Robbins MJ; Wall RA; Williams AH; Cremer AW; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(5):317-29. PubMed ID: 2941259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases.
    Hoshino K; Sato K; Akahane K; Yoshida A; Hayakawa I; Sato M; Une T; Osada Y
    Antimicrob Agents Chemother; 1991 Feb; 35(2):309-12. PubMed ID: 1850968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-quinolones and the physiology of DNA gyrase.
    Drlica K; Kreiswirth B
    Adv Pharmacol; 1994; 29A():263-83. PubMed ID: 7826862
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunological aspects of new quinolones.
    Shalit I
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):262-6. PubMed ID: 1864286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential.
    Corbett AH; Guerry P; Pflieger P; Osheroff N
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2599-605. PubMed ID: 8109923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems.
    Gootz TD; Barrett JF; Sutcliffe JA
    Antimicrob Agents Chemother; 1990 Jan; 34(1):8-12. PubMed ID: 2158274
    [No Abstract]   [Full Text] [Related]  

  • 17. [In vitro and in vivo antibacterial activities of a new quinolone derivative, FD501].
    Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
    Jpn J Antibiot; 1996 Mar; 49(3):264-72. PubMed ID: 8935122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-Quinolone interactions with gyrase subunit B inhibitors.
    Lewin CS; Howard BM; Smith JT
    J Med Microbiol; 1991 Dec; 35(6):358-62. PubMed ID: 1661337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinolone uptake by bacteria and bacterial killing.
    Diver JM
    Rev Infect Dis; 1989; 11 Suppl 5():S941-6. PubMed ID: 2549609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New quinolones: in vitro effects as a potential source of clinical toxicity.
    Forsgren A; Bredberg A; Riesbeck K
    Rev Infect Dis; 1989; 11 Suppl 5():S1382-9. PubMed ID: 2549607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.